[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"infectious-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:infectious-disease":23},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,17,0,[8,37,73,100,128,160,201,231,261,288,308,341,368,389,416,439,480],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":25,"lastUpdatePostDateStruct":26,"startDateStruct":29,"completionDateStruct":31,"leadSponsor":33,"locationsCount":36},"100598277","an-international-observational-study-of-adults-with-acute-infection-100598277",false,"NCT07069400","An International Observational Study of Adults With Acute Infection","Inclusion Criteria:\n\n* Age ≥18 years old\n* Admitted to hospital (or in an emergency department with anticipated hospital admission) for the management of a suspected or confirmed acute infectious disease.\n* Onset of symptoms of an infectious disease within the past 30 days.\n* Informed consent for study participation by the participant or a surrogate decision maker if the participant lacks capacity for consent.\n\nExclusion Criteria:\n\n* Current imprisonment (this does not include quarantine for an infectious disease).\n* Patient undergoing comfort care measures only such that treatment focuses on end- of-life symptom management over prolongation of life.\n* Expected inability or unwillingness to participate in study procedures.\n* In the opinion of the investigator, participation in the study is not in the best interest of the patient.","ALL","18 Years",{"count":18,"type":19},1500,"ESTIMATED","OBSERVATIONAL","Prospective, longitudinal studies of people with acute infections are essential to understand risk factors, clinical manifestations, pathobiology, and management strategies. Observational studies can provide data necessary to select interventions and strategies for testing in clinical trials and to develop key design features of trials. Observational studies can be particularly important for establishing an early knowledge base after emergence of a new pathogen, as illustrated by the recent emergence of influenza A (H1N1), SARS-CoV-2, and Mpox. This observational study protocol describes collection of data and biospecimens from sites across the world for characterizing acute infections in hospitalized patients. The protocol is designed to study respiratory infections, infections outside the respiratory tract, established infectious diseases, and emerging infectious diseases. Data generated in this study will be used to efficiently characterize acute infectious diseases and plan future clinical trials.",[23],"Infectious Disease","RECRUITING","2026-06-12",{"date":27,"type":28},"2026-06-15","ACTUAL",{"date":30,"type":28},"2025-08-25",{"date":32,"type":19},"2027-06-08",{"name":34,"class":35},"University of Minnesota","OTHER",50,{"id":38,"slug":39,"hasResults":11,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":43,"eligibilityCriteria":44,"healthyVolunteers":45,"sex":15,"minAge":46,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":57,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100555331","phase-2-pharmacogenomics-for-better-treatment-of-fungal-infections-clinical-trial-100555331","NCT06510699","Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial","Randomized Clinical Trial to Evaluate the Use of Genotype-based Dosing of Voriconazole","PRAGMATIC","Inclusion Criteria:\n\n* Age ≥ 2 years.\n* Written informed consent obtained.\n* Decision to prescribe voriconazole.\n* Admitted to a trial site, or sufficient outpatient follow-up appointments are feasible\n\nExclusion Criteria:\n\n* Post-allogeneic haematopoietic stem cell transplant (HCT) patient, without access to pre HCT DNA\n* Death is likely imminent within 7 days.\n* Previously randomised to this trial",true,"2 Years",{"count":48,"type":19},104,"INTERVENTIONAL",[51],"PHASE2","This project aims to address invasive fungal infections in patients, by precision dosing of voriconazole based on CYP2C19 genotype testing with Bayesian dose-forecasting dosing software to develop patient-centric and maximally effective dosing regimens. This study investigates if voriconazole increases the proportion of patients achieving therapeutic exposure at day 8 of dosing compared with standard care; and will assess factors that influence the implementation of genotype testing and dosing software in the healthcare system, including fidelity, feasibility, acceptability and cost-effectiveness. It will recruit at least 104 kids and adults in a parallel-group randomised clinical trial. A hybrid feasibility sub-study will assess the scalability of genotype-directed dosing to ensure sustainable integration of the interventions into the clinical workflow. A health economic sub-study will evaluate the costs, health outcomes and cost-effectiveness of genotype-directed testing compared to standard care.",[54,55,56,23],"Fungal Infection","Haematological Malignancy","Blood Cancer",[58,59,60,61,62],"infection","cancer","pharmacogenomic","genotype-based dosing","CYP2C19","2026-04-13",{"date":65,"type":28},"2026-04-16",{"date":67,"type":28},"2025-04-14",{"date":69,"type":19},"2027-03-26",{"name":71,"class":35},"The University of Queensland",7,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":15,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":49,"phases":84,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":99},"100548834","l-citrulline-to-improve-adverse-outcomes-in-admitted-children-echilibrist-clinical-trial-2-inpatients-100548834","NCT06426147","L-citrulline to Improve Adverse Outcomes in Admitted Children (EChiLiBRiST, Clinical Trial 2, Inpatients)","A Randomised, Double-blind, Placebo-controlled Trial of L-Citrulline Oral Supplementation to Improve Short and Long-term Outcomes of Admitted Febrile Paediatric Patients With Biomarker-determined High-risk of Adverse Outcomes","Inclusion Criteria:\n\n* Enrolled in the initial prognostic screening component.\n* Sick children with fever (axillary temperature\\>37.5ºC) or a history of fever (within the preceding 72h) or with suspected severe disease.\n* 1m-\\\u003C60 months of age.\n* With an indication for admission, or having already been admitted to hospital due to their illness.\n* With an sTREM-1 PoC result classifying their disease as of \"moderate-high risk\" (\"yellow\" or \"red\") upon study recruitment and within D3.\n* Residents in the study area or willing to be contacted and traced during the study duration.\n* Willing to sign an informed consent document.\n* Willing to undergo and adhere to study procedures as explained in the IC document.\n\nExclusion Criteria:\n\n* Admission to hospital for social reasons (and not on account of their disease).\n* Children for which informed consent document has not been signed.\n* Known allergy or contraindication to any of the study supplements including lactose intolerance or observing a lactose-free diet.\n* Concurrent participation in any other clinical trial.\n* Patient under NPO or \"nothing by mouth\" prescription .\n* Contraindication for the insertion of a nasogastric tube (NGT) of for the enteral administration of drugs through the NGT in children who cannot tolerate by mouth.\n* Critically sick patient whose prognosis is considered by the clinical researcher as fatal outcome in the following hours after screening.\n* Any other condition determined by the investigators that makes it unlikely that the participant would complete the follow up until day 28 of study.","0 Months","60 Months",{"count":83,"type":19},2200,[85],"NA","In low and middle-income countries, children admitted to hospital are not similarly ill, and do not all have a comparable prognosis. In fact, understanding at first encounter their risk of developing adverse outcomes (including mortality) could allow a more focused management and the tailoring of specific interventions to decrease in hospital mortality, and post discharge adverse longer-term outcomes. This clinical trial, part of the EChiLiBRiST larger project (\"Development and validation of a quantitative point-of-care test for the measurement of severity biomarkers to improve risk stratification of fever syndromes and enhance child survival\") has the two-fold objective of:\n\n1. Assessing whether a POINT-OF-CARE rapid triaging test (PoC RTT) based on the quantitative measurement at the bedside of the \"prognostic\" biomarker sTREM-1 (soluble-triggering receptor expressed on myeloid cells 1) can reliably identify those admitted children with a higher risk of adverse outcomes; and\n2. Assessing whether the therapeutic intervention (the L-arginine precursor, L-Citrulline, key in the nitric oxide biosynthesis), administered orally for 28 days to those children aged 1-\\\u003C60 months identified as \"moderate-to-high risk\" by the prognostic biomarker can improve outcomes as compared to those receiving an indistinguishable placebo.\n\nThis second objective will be assessed in a prospective multi-country, multi-site, individually randomised, two-arm, placebo-controlled, double blind clinical trial involving \\~888 children 1-\\\u003C60m of age admitted to hospital and determined to be at high risk of adverse outcomes by their baseline sTREM-1 levels. The trial will compare the efficacy of a twice-daily dose of L-citrulline syrup vs placebo (200-300mg\u002Fkg\u002Fday depending on weight-band; for 28 days) in reducing adverse outcomes in children with severe disease. The trial will be running independently but in parallel in two high-mortality settings in Mozambique and in Ethiopia.",[23,88,89],"Infections","Child, Only","2026-02-19",{"date":92,"type":28},"2026-02-23",{"date":94,"type":28},"2025-12-08",{"date":96,"type":19},"2027-08-01",{"name":98,"class":35},"Barcelona Institute for Global Health",2,{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":15,"minAge":107,"maxAge":81,"enrollmentInfo":108,"targetDuration":4,"studyType":49,"phases":110,"briefSummary":111,"conditions":112,"keywords":114,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":99},"100548541","a-rapid-triage-test-to-improve-risk-stratification-of-febrile-children-echilibrist-clinical-trial-1-outpatients-100548541","NCT06422338","A Rapid Triage Test to Improve Risk-stratification of Febrile Children (EChiLiBRiST, Clinical Trial 1, Outpatients)","A Multi-country, Two-arm, Open-label, Superiority, Randomised Controlled Trial to Study the Performance of a Rapid Triage Test Compared to Standard of Care (IMCI-based) to Guide Admission\u002FDischarge Decisions During the First Clinical Assessment of Children With Fever","Inclusion Criteria:\n\n* Age ≥2 months and \\\u003C60 months\n* Written informed consent from the child's parent or caregiver\n* History of fever for ≤7 days OR hypothermia (i.e., axillary temperature \\\u003C35.5ºC) OR suspected severe infection (e.g., in children with moderate or severe acute malnutrition).\n* Lives within the catchment area of the study facility and must intend to continue to reside there for the duration of the study\n* For the RTI sub-study only: presence of respiratory symptoms compatible with RTI.\n\nExclusion Criteria:\n\n* Weight less than 2.5kg\n* Main reason for consultation is an injury, trauma or acute poisoning\n* Enrolled in another clinical trial testing a new drug\n* Enrolled in a vaccine trial in the last 3 months.\n* Any other condition determined by the investigators that makes it unlikely that the participant would complete the study","2 Months",{"count":109,"type":19},5212,[85],"The overall aim of the study is to provide evidence that introducing novel biomarkers evaluation at triaging (first clinical assessment), in combination with IMCI-based guidelines (SoC), is a viable strategy to enhance rapid and accurate identification of febrile children at increased risk of life-threatening infections compared to IMCI-based strategies alone (SoC), and to demonstrate whether this results in enhanced decisions of admission\u002Freferral vs discharge, and enhanced overall health outcome of children with acute fever in sub-Saharan Africa.",[23,113,89],"Febrile Illness",[115,116,117,118,119],"biomarkers","severity","point-of-care","triage","sub-Saharan Africa","2026-02-12",{"date":122,"type":28},"2026-02-17",{"date":124,"type":28},"2025-07-02",{"date":126,"type":19},"2027-03-01",{"name":98,"class":35},{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":45,"sex":15,"minAge":16,"maxAge":136,"enrollmentInfo":137,"targetDuration":4,"studyType":49,"phases":139,"briefSummary":141,"conditions":142,"keywords":144,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":159},"100517967","phase-1-evaluation-of-tolerance-and-pharmacokinetic-profile-of-high-doses-of-favipiravir-in-healthy-volunteers-100517967","NCT06024421","Evaluation of Tolerance and Pharmacokinetic Profile of High Doses of Favipiravir in Healthy Volunteers","EVALUATION DE LA TOLERANCE ET DU PROFIL PHARMACOCINETIQUE DE DOSES ELEVEES DE FAVIPIRAVIR CHEZ LE VOLONTAIRE SAIN","FAVIDOSE","Inclusion Criteria:\n\n1. Man between 50 and 75 years old without any desire to have children or woman between 18 and 75 years old ;\n2. Subject considered healthy after a thorough general examination (questioning, physical examination);\n3. For men: acceptance of semen collection by masturbation;\n4. For men: acceptance of condom use from initiation of the investigational drug until 1 month after stopping the investigational drug;\n5. For women of childbearing potential: effective contraceptive method combining two methods of contraception (one female contraceptive method combined with male condom use) from the inclusion visit until 1 month after discontinuation of the investigational drug;\n6. Blood chemistry:\n\n   * Kalemia, Calcemia, Prothrombin rate (PT), Activated partial thromboplastin time (APTT): values within laboratory normal;\n   * ALT, ASAT, Uricemia: values below the upper limit of the laboratory normal;\n   * Other biological results (Blood count; Natremia; Phosphoremia; Chloremia; Fasting blood glucose; Gamma glutamyl transpeptidase; Urea; Total bilirubin; Creatinine; CPK; Lactate dehydrogenase; Albuminemia; Proteinemia; Triglycerides; C-reactive protein; Albumin\u002FGlobulin ratio; Alkaline phosphatase) with no clinically significant abnormality.\n\n   NB: A parameter outside the usual values considered clinically significant may, at the investigator's discretion, be tested a second time on another sample taken outside of a visit planned in the protocol before the initiation of the experimental drug.\n7. Urine dipstick (biochemistry: leukocyturia, proteinuria and hematuria) without clinically significant abnormality;\n8. Urine tox screen negative (amphetamines\u002Fmetamphetamines, barbiturates, benzodiazepines, cannabis, cocaine, opiates);\n9. Ability to take the investigational drug orally and adherence to the dosage of the investigational drug;\n10. Acceptance and signing of the informed consent;\n11. Membership in a social security plan or beneficiary of such a plan;\n12. Adherence to lifestyle considerations (see section 5.5) during participation in this research.\n\nExclusion Criteria:\n\n1. Concomitant use or within 15 days prior to inclusion of another QT\u002FQTc prolonging drug or drugs that may disrupt electrolyte levels, among others: loop diuretics, thiazide diuretics and related drugs (see list www.crediblemeds.org)\n2. History of amiodarone use within 6 months prior to inclusion\n3. History of gout or current treatment for gout or hyperuricemia\n4. Treatment with pyrazinamide or any other drug known to induce hyperuricemia\n5. History of hypersensitivity reaction to a nucleoside analog targeting viral RNA polymerase\n6. Known hypersensitivity to any of the components (favipiravir or placebo)\n7. Pregnant or breastfeeding women\n8. For men: history of vasectomy or known history of infertility.\n9. Refusal of the subject to complete all the visits, clinical and paraclinical examinations planned by the study\n10. On ECG: PR \\>200ms, QRS \\>100ms QTc \\>450ms and morphological appearance of abnormal repolarization\n11. PAS \\\u003C100 mmHg\n12. Any history or active cardiovascular, pulmonary, intestinal, hepatic, renal, metabolic, hematologic, neurologic, bone, joint, muscular, psychiatric, systemic, ocular, gynecologic, andrologic, or infectious disease (including active HIV, HCV, or HBV infection), or any acute condition, which in the judgment of the investigator could be detrimental to the volunteer and\u002For interfere with or limit the protocol evaluation and data analysis\n13. Personal or family history of long QT syndrome, torsades de pointes or sudden death\n14. Patient with severe hepatic impairment\n15. Gastrointestinal pathology such as ileus, colitis or enterocolitis\n16. Treatment with another investigational drug or other investigational procedure (clinical trial, clinical investigation of a medical device, category 1 or 2 research involving humans);\n17. A person who is subject to a legal protection measure (safeguard of justice, curatorship, guardianship);\n18. Person placed in administrative detention;\n19. Person who, in the judgment of the investigating physician, may be non-observant during the study, or unable to communicate due to a language barrier or mental disorder\n20. Person who cannot be contacted in an emergency\n21. Person with at least one first-degree relative from East Asia or Southeast Asia.\n\nSecondary Exclusion Criteria\n\nParticipants with at least one of the following criteria will not start the experimental treatment at D1 if they are already randomized:\n\n1. Positive nasopharyngeal antigen test for SARS-CoV-2 at D1 (prior to treatment initiation)\n2. Blood potassium levels outside the normal laboratory range within 8 days prior to treatment initiation (D1)\n3. ECG: PR \\>200ms, QRS \\>100ms QTc \\>450ms and morphological appearance of abnormal repolarization on Day 1\n4. Positive pregnancy test on Day 1 (before initiation of treatment)","75 Years",{"count":138,"type":19},39,[140],"PHASE1","FAVIDOSE trial is a Phase I randomized, double blind controlled, monocentric, dose escalation clinical trial. The primary purpose of this trial is to evaluate tolerance of high doses of favipiravir for 14 days in healthy volunteers. This trial also looks to characterize favipiravir pharmacokinetics in blood and favipiravir levels in sperm. A pharmacogenetics analysis will be conducted in an attempt to identify genetic variants of metabolism and transport enzymes of favipiravir to explain the inter-individual variability of pharmacokinetic parameters of favipiravir.\n\nThree sequential dose levels including distinctive participants:\n\n* level 1: D1: 2400 mg BID; D2 to D13: 1600 mg BID and D14: 1600 mg in the morning;\n* level 2: D1: 2400 mg BID; D2 to D13: 2000 mg BID and D14: 2000 mg in the morning;\n* level 3: D1: 2400 mg BID; D2 to D13: 2400 mg BID andD14: 2400 mg in the morning.\n\nThree study groups of maximum of 8 participants, 6 receiving favipiravir and 2 receiving placebo per dose level, three dose levels proposed. Seven additional participants with the same follow up will be included and randomized (6:1 ratio) at the maximum tolerated dose level to allow a satisfactory accurate characterization of pharmacokinetics and pharmacogenetics of favipiravir and their determinants (maximum 39 participants in total, taking into account 8 participants - 2 per dose level - replaced because loss of follow-up before the end of treatment).",[23,143],"Pharmacology",[145,146,147,148,149],"healthy volunteer","dose escalation","tolerance","pharmacokinetics","favipiravir","2026-02-10",{"date":120,"type":28},{"date":153,"type":28},"2024-05-14",{"date":155,"type":19},"2027-11",{"name":157,"class":158},"Institut National de la Santé Et de la Recherche Médicale, France","OTHER_GOV",1,{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":168,"targetDuration":170,"studyType":20,"phases":4,"briefSummary":171,"conditions":172,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":200},"100450503","cytosorb-treatment-of-critically-ill-patients-registry-100450503","NCT05146336","CytOSorb TreatMent Of Critically Ill PatientS Registry","CytOSorb TreatMent Of Critically Ill PatientS Registry: International Registry on the Use of CytoSorb in the Critical Care Setting","COSMOS","Inclusion Criteria:\n\n1. Planned OR actual CytoSorb® 300 mL device utilization\n2. Informed consent for prospective registry participation\n\nExclusion Criteria:\n\n1. Use of the CytoSorb® 300 mL device for antithrombotic removal only\n2. Intraoperative use of CytoSorb® 300 mL device during cardiac surgery only\n3. The occurrence of a complication or other medically justified circumstance that arises after written informed consent has been obtained from the patient and before or during the planned therapy and as a result of which the use of CytoSorb® 300 mL Adsorber is contraindicated or no longer appropriate.",{"count":169,"type":19},3000,"3 Months","Registry intended to provide a data repository and reporting infrastructure for the surveillance of CytoSorb device use in real-world critical care settings, and to serve as an objective, comprehensive, and scientifically-based resource to measure and improve the quality of patient care",[173,174,175,176,177,178,179,180,181,182,183,184,185,186,23,187,188,189],"Septic Shock","Acute Respiratory Distress Syndrome","Trauma","Rhabdomyolysis","Cardiogenic Shock","Pancreatitis","Acute on Chronic Liver Failure","Acute Liver Failure","Burns","Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Cytokine Release Syndrome (CRS)","Extracorporeal Life Support","Postoperative Endocarditis","Hemophagocytic Lymphohistiocytoses","Liver Transplant; Complications","Postoperative Vasoplegic Syndrome","Drug Overdose","Sepsis","2025-09-10",{"date":192,"type":28},"2025-09-11",{"date":194,"type":28},"2022-06-22",{"date":196,"type":19},"2032-09",{"name":198,"class":199},"CytoSorbents, Inc","INDUSTRY",28,{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":205,"acronym":206,"eligibilityCriteria":207,"healthyVolunteers":11,"sex":15,"minAge":208,"maxAge":209,"enrollmentInfo":210,"targetDuration":4,"studyType":49,"phases":212,"briefSummary":214,"conditions":215,"keywords":218,"overallStatus":221,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":159},"100497933","phase-4-vitality-in-infants-via-azithromycin-for-neonates-trial-100497933","NCT05763693","Vitality in Infants Via Azithromycin for Neonates Trial","VIVANT","Inclusion Criteria:\n\n* Aged 1-27 days old\n* Birthweight \\\u003C 2500 g and\u002For weight-for-height Z score \\\u003C- 2 standard deviations at enrollment\n* Weigh at least 1500 g at time of enrollment\n* Able to feed orally\n* Family intends to stay in the study area for at least 6 months\n* Written informed consent from at least one caregiver\n* Afebrile\n* Caregiver at least 18 years old\n* No known allergy to macrolides\n* No hepatic failure manifested by neonatal jaundice\n* Not currently an inpatient at the clinic\n* Not being transferred to a hospital for clinical complications\n\nExclusion Criteria:\n\n* Birthweight \\> 2500 g\n* Weigh less than 1500 g at time of enrollment\n* Unable to feed orally\n* Family planning to move within 6 months\n* Mother\u002F caregiver not willing to participate\n* Allergic to macrolides\n* Hepatic failure manifested by neonatal jaundice\n* Currently being seen as an inpatient at the clinic\n* Currently being transferred to a hospital for clinical complications","1 Day","27 Days",{"count":211,"type":19},4000,[213],"PHASE4","Nearly half of child deaths occur during the neonatal period, and 80% of those occur in babies with low birthweight. Although tremendous progress has been made towards reducing under-five mortality globally, declines in neonatal mortality lag behind those observed in older children. Low birthweight babies are at increased risk of poor outcomes compared to those who are term-appropriate for gestational age, including mortality, stunting, and growth failure. Recent evidence has demonstrated that the incidence of wasting and linear growth failure is highest between birth and 3 months of age, substantially earlier than previously thought. Interventions are urgently needed to improve outcomes in low birthweight babies; however, these interventions must not interfere with breastfeeding and thus some well-established interventions used to treat or prevent malnutrition in older children cannot be considered. The investigators recently demonstrated that biannual mass azithromycin distribution reduces all-cause childhood mortality by approximately 25% in infants aged 1-5 months, with stronger effects seen in underweight infants. This study did not include neonates due to the risk of infantile hypertrophic pyloric stenosis (IHPS) that has been hypothesized to be associated with macrolide use during early infancy. However, our study team documented only a single case of IHPS among 21,833 neonates enrolled in a trial of azithromycin versus placebo administered to neonates aged 8-27 days for prevention of infant mortality, documenting no major risk of IHPS associated with azithromycin. Here, the investigators propose an individually randomized trial where participants will receive a single oral dose of azithromycin (administered either during the neontal period or 21 days after enrollment), two does of oral azithromycin spaced 21 days apart, or two doses of placebo to evalute if azithromycin improves nutritional outcome and reduces infectious burden among neonates aged 1-27 days who are either low birthweight (\\\u003C2500 g at birth) or underweight (weight-for-age Z-score \\\u003C -2 at enrollment). The primary outcome will be weight-for-age Z-score at 6 months of age compared between arms. The investigators anticipate that the results of this study will provide definitive evidence on azithromycin as an early intervention for low birthweight\u002Funderweight neonates, who are at the highest risk of adverse outcomes.",[216,23,217],"Neonatal Death","Nutritional Deficiency",[219,220],"Low birth weight","underweight neonates","NOT_YET_RECRUITING","2025-08-28",{"date":224,"type":28},"2025-08-29",{"date":226,"type":19},"2026-04",{"date":228,"type":19},"2030-04",{"name":230,"class":35},"University of California, San Francisco",{"id":232,"slug":233,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":237,"eligibilityCriteria":238,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":239,"targetDuration":4,"studyType":49,"phases":241,"briefSummary":242,"conditions":243,"keywords":247,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":260},"100442763","phase-4-antibiotic-therapy-in-viral-airway-infections-100442763","NCT05045612","Antibiotic Therapy in Viral Airway Infections","Antibiotic Therapy in Viral Airway Infections: An Open Labeled Randomized Controlled Pragmatic Trial to Evaluate the Efficacy and Safety of Discontinuing Antibiotic Therapy in Adult Patients With Respiratory Viruses","ATHENIAN","Inclusion Criteria:\n\n* Hospitalized\n* Adults 18 year or older\n* Moderately severe disease (CRB65 ≤ 2 at time of inclusion)\n* Nasopharyngeal swab positive for influenza virus, parainfluenza virus, respiratory syncytial virus (RSV) or human metapneumovirus (hMPV)\n* On antibiotic therapy as instituted by the receiving physician from the emergency department\n* Signed informed consent must be obtained and documented according to ICH GCP, and national\u002Flocal regulations.\n\nExclusion Criteria:\n\n* Requiring ICU admission at screening\n* Requiring high-flow oxygen therapy or non-invasive ventilation at screening\n* Signs of severe pneumonia (abscesses, massive pleural effusion, a well-defined lobar infiltrate on chest X-ray strongly suggestive of bacterial etiology)\n* Not immunocompetent (i.e. on active chemotherapy, corticosteroid therapy equaling ≥ 20 mg prednisolone daily for ≥ 4 weeks, chronic immunosuppression due to solid organ transplant)\n* SARS-CoV-2 positive\n* Bacteremia\n* Urine antigen test positive for legionella\n* Any other infection necessitating antibiotic treatment\n* Antibiotic use for assumed airway infection within the last 24 hours before admission to hospital\n* Time from initiation of antibiotic therapy to screening \\>48 hours",{"count":240,"type":19},380,[213],"Antimicrobial resistance is one of the most urgent health threats of our time, and Norwegian hospitals were required to reduce the use of broad-spectrum antibiotics with 30% by the end of 2020. In the current proposal, the investigators aim to assess the efficacy and safety of early discontinuation of antibiotic therapy in adult patients infected with respiratory viruses.\n\nA general recommendation to treat all instances of community acquired pneumonia (CAP) patients with antibiotics leads to significant antibiotic overtreatment. In 2008, the US Food and Drug Administration approved the first multiplex polymerase chain reaction assay for the detection of multiple respiratory virus nucleic acids simultaneously. The wide availability of such nucleic acid amplification tests (NAAT) for rapid viral detection together with chest radiographs has the potential to define patients who can be managed without antibiotics.\n\nAkershus University Hospital is one of the largest hospitals in Norway, with a catchment area of more than 550,000 people. In 2012 to 2013, the majority of patients admitted to Akershus University Hospital with suspected CAP and a positive viral NAAT were treated with antibiotics, a prescription pattern representing antibiotic overtreatment. The investigators accordingly hypothesize that discontinuation of antibiotic therapy in patients with moderately severe disease and airway sample positive for respiratory viruses is safe and non-inferior to continuation of antibiotic therapy.",[23,244,245,246],"Influenza","Respiratory Syncytial Virus (RSV)","Respiratory Tract Infections",[248,249,250],"pragmatic trial","antibiotic stewardship","viral respiratory tract infection","2025-08-11",{"date":253,"type":28},"2025-08-12",{"date":255,"type":28},"2022-01-13",{"date":257,"type":19},"2029-11",{"name":259,"class":35},"University Hospital, Akershus",12,{"id":262,"slug":263,"hasResults":11,"nctId":264,"briefTitle":265,"officialTitle":265,"acronym":266,"eligibilityCriteria":267,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":268,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":270,"conditions":271,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":99},"100499195","prospective-observational-study-to-characterize-patients-treated-at-internal-medicine-clinics-100499195","NCT05780099","Prospective Observational Study to Characterize Patients Treated at Internal Medicine Clinics","MED-Cli","Inclusion Criteria:\n\n* Receving treatment at internal medicine departments (inpatient, outopatient, day hospital) of San Raffaele Hospital\n* at least one suspected or confirmed diagnosis among:\n\n  1. immune mediated disorder\n  2. respiratory disorder\n  3. metabolic disorder\n  4. sepsis\n  5. rare disorder (according to Italian Ministry of Health list)\n  6. pregnancy-related disorder\n  7. frailty defined as: either ≥2 CIRS (Cumulative Illness Rating Scale) Severity Index 10 or ≤70% Karnofsky scale\n\nExclusion Criteria:\n\n* refusal to participate\n* enrolment in other intervantional study",{"count":269,"type":19},50000,"Patients referred to internal medicine wards are becoming increasingly complex and fragile. Despite deep knowledge of their specific disorders, steps are required to improve overall management of their acute and chronic conditions. The main objective of the study is to identify demographic, clinical, laboratory and radiological markers of disease severity and activity in patients with diseases treated at general medicine wards (respiratory disease, immune-mediated disease, sepsis, metabolic disease, rare disease, frailty, pregnancy pathology) in order to improve their diagnosis, monitoring and treatment processes.",[272,273,23,274,275,276,277,278],"Respiratory Disease","Cardiovascular Diseases","Critical Illness","Immunological Disease","Pregnancy Disease","Metabolic Syndrome","Chronic Disease","2025-06-17",{"date":281,"type":28},"2025-06-22",{"date":283,"type":28},"2022-06-24",{"date":285,"type":19},"2032-09-10",{"name":287,"class":35},"IRCCS San Raffaele",{"id":289,"slug":290,"hasResults":11,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":294,"eligibilityCriteria":295,"healthyVolunteers":45,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":296,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":298,"conditions":299,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":307,"locationsCount":159},"100523927","genetic-susceptibility-to-severe-infections-100523927","NCT06102070","Genetic Susceptibility to Severe Infections","Genetic Susceptibility to Severe Infections Including in Particular but Not Exhaustively All Types of Viral, Bacterialn and Fungal Infections.","PREDISPOSITI","Inclusion Criteria:\n\n* to sign the informed consent signed by the patient. In the case of a minor patient, consent is signed by the holders of parental authority. In the case of a protected adult patient, the consent is signed by their legal representative. In the case of an adult patient unable to consent at the time of inclusion, consent is signed by a family member.\n* to have a proven rare and severe infection\n* to be hospitalized or followed in a specialized hospital department, in the emergency room or in intensive care\n* to be affiliated to the French Social Security system\n* for relatives, to be related to the index case up to the 3rd degree: Parents, Children, Brother, Sister, Grandparents, Uncles, Aunts, Cousins, Nephews, Nieces\n\nExclusion Criteria\n\n* to have an acquired immunodeficiency (having received immunosuppressive treatment in the 3 months preceding the onset of the disease or being HIV positive)\n* pregnant woman at the time of illness",{"count":297,"type":19},2000,"Only a fraction of individuals infected with microbes develop clinical disease. This observation raises fundamental questions about the pathogenesis of infectious diseases. There is a complex interaction between environmental (microbial and non-microbial) and human (genetic and non-genetic) factors. This will determine the quality of the immune response against the infectious agent and the clinical manifestation. By definition, individuals who die from an infection have defective immunity to the pathogen in question (immune agent (immune deficiency).\n\nThe investigation of individual variability in the development of infectious diseases began in the early 20th. The first evidence to support the hypothesis that individual variability variability and immune deficiencies were hereditary came from observations of familial cases or genetic isolates genetic isolates (from a homogeneous population) of rare or common infectious diseases, which in some cases Mendelian heredity hat predisposition to infectious diseases runs in families even more so than diseases associated with less determined environmental factors, such as certain cancers. such as certain cancers. Finally, studies comparing the rate of concordance of infectious diseases between monozygotic and dizygotic twins also implicate genetic factors in disease susceptibility.\n\nThese observations were validated by the discovery of genetic defects associated with severe infectious diseases, leading to proof of concept. While a number of hereditary immune deficiencies associated with susceptibility to multiple pathogens or microorganisms, a growing number of new and rare new and rare immune deficiencies conferring restricted susceptibility to infections caused by a single caused by a single pathogen family, or even a single pathogen, in otherwise healthy children, have recently been identified (one gene, one pathogen). As a result, a dozen Mendelian clinical syndromes characterized by restricted susceptibility are now known. Over the last 20 years, it has been proven that these \"idiopathic\" infections were immune deficiencies.\n\nThe investigators now wish to study new severe infections, including but not limited to viral, fungal and bacterial infections. viral, fungal, bacterial and parasitic infections. This should lead to a better understanding of the pathophysiology of each disease, the development of new therapeutics and better patient care.",[23],"2025-03-18",{"date":302,"type":28},"2025-03-19",{"date":304,"type":28},"2022-02-18",{"date":306,"type":19},"2038-10-18",{"name":157,"class":158},{"id":309,"slug":310,"hasResults":11,"nctId":311,"briefTitle":312,"officialTitle":313,"acronym":314,"eligibilityCriteria":315,"healthyVolunteers":11,"sex":15,"minAge":316,"maxAge":317,"enrollmentInfo":318,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":320,"conditions":321,"keywords":325,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":332,"lastUpdatePostDateStruct":333,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":339,"locationsCount":159},"100426957","dengue-vaccine-strategy-in-children-aged-9-to-17-years-in-the-french-caribbean-100426957","NCT04839757","Dengue Vaccine Strategy in Children Aged 9 to 17 Years in the French Caribbean","Preparing for the Use of a Dengue Vaccine in the French Caribbean Islands of Martinique and Guadeloupe : the DengueSEA Study","DengueSEA","CHILDREN\n\nInclusion Criteria for children:\n\n* Any child aged 9 to 17 years presenting to one of the hospital departments participating in the study at the University Hospitals of Martinique or Guadeloupe\n* Need to take a blood sample or place a peripheral venous line for the management of the child\n* Residence in Martinique or Guadeloupe since at least one year\n* Information on the study given to the child and his\u002Fher parent or legal guardian\n* Collection of the parent's or legal guardian's non-objection to the child's participation\n\nExclusion Criteria for children:\n\n* Presence of fever or suspected acute infection\n* Presence of an immune deficiency or any other dysimmune condition\n\nPARENTS\n\nParental inclusion criteria (\"vaccine acceptability\" survey)\n\n* Collection of the parent's or legal guardian's non-objection to participate in the Dengvaxia® vaccine acceptability survey\n* Comprehension of spoken and written French\n\nNon-inclusion criteria for parents (vaccine acceptability survey)\n\n\\- None of the above","9 Years","17 Years",{"count":319,"type":19},590,"Dengue fever, an arbovirus transmitted by the Aedes mosquito, is a public health problem in all tropical and subtropical regions of the world. There is currently no antiviral treatment and vector control has shown its limits. The 2018 European marketing authorization of the tetravalent chimeric yellow fever \u002F dengue vaccine (Dengvaxia®) is a major step forward in the fight against the disease. Dengvaxia® is indicated for the prevention of dengue due to serotypes DENV 1-4 in subjects aged 9 to 45 years with a history of infection with the dengue virus and living in endemic areas (seroprevalence of at least 70% in the target population).\n\nDengue seroprevalence data in the French Caribbean territories of Martinique and Guadeloupe dates back to 2011 and concerns only adult blood donors aged 18 to 70 years. To date, no data exists for individuals aged 9 to 17 years in the region.\n\nIn order to implement an optimal vaccine introduction strategy for these territories, the main aim of the DengueSEA study is to estimate the seroprevalence of the Dengue viruses (DENV 1-4) in 9-17 year olds giving a blood sample as part of care in hospital departments of the French Caribbean islands of Martinique and Guadeloupe.",[322,323,324,23],"Dengue","Vaccination","Seroprevalence",[326,327,328,329,330,331],"dengue","seroprevalence","children","adolescents","vaccination strategy","French Carribean","2025-02-20",{"date":334,"type":28},"2025-02-21",{"date":336,"type":28},"2021-06-03",{"date":338,"type":19},"2026-02",{"name":340,"class":35},"University Hospital Center of Martinique",{"id":342,"slug":343,"hasResults":11,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":347,"eligibilityCriteria":348,"healthyVolunteers":45,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":349,"targetDuration":4,"studyType":49,"phases":351,"briefSummary":353,"conditions":354,"keywords":356,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":360,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":366,"locationsCount":99},"100513999","phase-2-rickettsia-clearance-study-100513999","NCT05972772","Rickettsia Clearance Study","A Pharmacokinetic-pharmacodynamic Study of Early Rickettsia Clearance in Murine Typhus or Scrub Typhus Patients Treated with Doxycycline or Azithromycin","RiCS","Inclusion Criteria:\n\n* Age above or equal 18 years\n* Able to take oral medication\n* Rapid test positive for murine typhus or scrub typhus\n* Agrees to stay in hospital for at least 36 hours and to attend for scheduled follow up visits\n* Written informed consent to participate in the study\n* A negative urinary pregnancy test for all women of child-bearing age\n\nExclusion Criteria:\n\n* Pregnancy or breast feeding\n* Previous allergic reaction to doxycycline or azithromycin\n* Received more than one dose of chloramphenicol, doxycycline, tetracycline, fluoroquinolones, rifampicin or azithromycin during this hospital admission or more than one dose of any of these drugs in the week before admission\n* Contraindication to doxycycline: severe hepatic impairment, known SLE\n* Contraindication to azithromycin: sever hepatic impairment\n* Severe typhus defined as the presence of one or more of the following:\n\n  1. Reduced level of consciousness\n  2. Clinical jaundice\n  3. Shock (BP systolic \\\u003C80 mmHg)\n  4. Unable to take oral medication\n  5. Radiological evidence of pneumonia\n  6. Clinical evidence for meningitis\u002Fencephalitis or the need of LP\n  7. Alternative diagnosis confirmed that explains the presenting symptoms\n  8. Any other syndrome which in the opinion of the admitting doctor constitutes severe typhus (reason must be stated)",{"count":350,"type":19},72,[51,352],"PHASE3","Murine typhus is a disease caused by Rickettisa typhi, an obligate intracellular bacterium transmitted by rodent fleas. The disease has a worldwide distribution; however the true burden is unknown, related to its non-specific presentation and lack of access to diagnosis in many regions. A systematic review of untreated murine typhus based on observational studies of a total of 239 patients has estimated the mortality associated with the disease at between 0.4% and 3.6%.\n\nScrub typhus is caused by Orientia tsutsugamushi and transmitted by the larval stage of chigger mites (Trombiculidae family). It has been estimated to affect at least one million people each year. A systematic review found varying reports of the mortality associated with untreated scrub typhus ranging from 0-70% (median 6%).\n\nPolymerase chain reaction (PCR) based diagnosis of rickettsial infections is only available in one centre (Mahosot Hospital) in Vientiane. A number of hospitals use a variety of point-of-care antibody tests to diagnose rickettsial infections however many of these have not been validated and they are of uncertain sensitivity and specificity. In 2006 results of a two year prospective study of 427 patients presenting to Mahosot Hospital with a febrile illness and negative blood cultures showed that 115 (27%) patients had an acute rickettsial infection, confirmed by serological testing. Among these patients, 41 were diagnosed with murine typhus and 63 with scrub typhus. Antibacterial agents with activity against rickettsial pathogens include doxycycline, azithromycin, chloramphenicol and rifampicin. Azithromycin is often reserved for pregnant women or children below the age of 8 years due to lasting concerns after the tetracycline-associated staining of growing bones and teeth in the past. Evidence is accumulating that doxycycline is superior to azithromycin for the treatment of rickettsial disease. Clinical treatment failures have occurred following azithromycin treatment of murine typhus. The relationship between rickettsial bacteria load and both disease severity and response to treatment has not been characterised. Rickettsial concentrations in blood are generally low, of the order of 210 DNA copies\u002FmL blood for R. typhi and 284 DNA copies\u002FmL blood for O. tsutsugamushi. At present, there is no standard antibiotic susceptibility testing (AST) method for R. typhi and O. tsutsugamushi. The gold standard method for AST for Rickettsia pathogens is the plaque assay which determines minimal inhibitory concentration (MICs) from the smallest antimicrobial concentration inhibiting rickettsial plaque forming unit formation. This method is laborious and time consuming, taking approximately 14-16 days based on species to yield a result. Molecular detection methods are useful for diagnosing patients infected with rickettsial pathogens and has been applied for antibiotic susceptibility testing. Antibiotic susceptibility testing based on DNA synthesis inhibition detecting by quantitative PCR (qPCR) for O. tsutsugamushi clinical isolates has been reported. However, the relationship between antibiotic susceptibility profiles and treatment response has not been studied. There is a need to develop a reliable ex vivo method to characterize the treatment response and compare susceptibility of R. typhi and O. tsutsugamushi to different agents.",[23,355],"Therapeutics",[357,358],"Scrub Typhus","Typhus, Endemic Flea-Borne","2024-12-23",{"date":361,"type":28},"2024-12-27",{"date":363,"type":28},"2024-11-01",{"date":365,"type":19},"2026-08-31",{"name":367,"class":35},"Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit",{"id":369,"slug":370,"hasResults":11,"nctId":371,"briefTitle":372,"officialTitle":373,"acronym":4,"eligibilityCriteria":374,"healthyVolunteers":45,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":375,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":376,"conditions":377,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":380,"lastUpdatePostDateStruct":381,"startDateStruct":383,"completionDateStruct":385,"leadSponsor":387,"locationsCount":159},"100390482","compliant-analysis-of-patient-samples-and-data-100390482","NCT04364503","Compliant Analysis of Patient Samples and Data","Use of Patient Samples and Corresponding Clinical Data for Research and Development Studies And\u002For Population-based Analysis","Inclusion Criteria:\n\n* Arm 1\n* All samples and data are de-identified and HIPAA compliant\n* Arm 2\n* Subject is of scientific interest to the Sponsor or treating physician\n* Subject provides written informed consent and has a clinical sample and\u002For supporting clinical data collected.\n\nExclusion Criteria:\n\n* Arm 1\n* Subject is from a US state or a country where local law restricts the use of de-identified data and\u002For remnants of specimens for research and\u002For development\n* Arm 2\n* Any medical or mental condition that would interfere with the subjects' ability to willingly give written informed consent",{"count":297,"type":19},"Patients of scientific interest who have provided a commercial sample to LabCorp or one of its' affiliates will have their de-identified remnant samples and\u002For data used for research and development. Other commercial patients will be followed up on after informed consent is obtained.",[378,379,23],"Pregnancy Related","Cancer","2024-10-11",{"date":382,"type":28},"2024-10-16",{"date":384,"type":28},"2018-03-17",{"date":386,"type":19},"2030-08-15",{"name":388,"class":199},"Sequenom, Inc.",{"id":390,"slug":391,"hasResults":11,"nctId":392,"briefTitle":393,"officialTitle":393,"acronym":394,"eligibilityCriteria":395,"healthyVolunteers":11,"sex":15,"minAge":396,"maxAge":4,"enrollmentInfo":397,"targetDuration":4,"studyType":49,"phases":399,"briefSummary":400,"conditions":401,"keywords":402,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":408,"startDateStruct":410,"completionDateStruct":412,"leadSponsor":414,"locationsCount":72},"100516455","antibiotics-for-delirium-in-older-adults-with-no-clear-urinary-tract-infection-100516455","NCT06004739","Antibiotics for Delirium in Older Adults With No Clear Urinary Tract Infection","A-DONUT","Inclusion criteria\n\n* Age ≥ 60 and admitted to a hospital ward (including rehabilitation hospital);\n* Active delirium (defined by CAM: \\[1\\] inattention AND \\[2\\] acute and fluctuating level of consciousness, and either \\[3\\] disorganized thinking OR \\[4\\] altered mental status; OR physician's diagnosis)\n* Less than 24 hours of antibiotics (prior to trial assessment)\n* Either pyuria (defined as white blood cells detected on urinalysis or dipstick) or bacteriuria (defined as bacteria growing on urine culture)\n\nExclusion criteria\n\n* Fever (temperature \\> 37.9C or \\> 100.2F) in the past 48 hours;\n* Signs of lower urinary tract infection symptoms (such as new dysuria) or upper urinary symptoms (such as costovertebral tenderness)\n* In the opinion of the treating physician, there is a reason apart from delirium and urine test results to treat with antibiotics (e.g., pneumonia)\n* Indwelling urinary catheter for \\> 72 hours\n* Receipt of an antibiotic where a single dose suffices for the treatment of a UTI (such as Fosfomycin)","60 Years",{"count":398,"type":19},550,[85],"Delirium is an acute confusional state that is experienced by many older adults who are admitted to hospital. To treat delirium the underlying cause needs to be identified promptly, but this is challenging. One of the potential causes of delirium is infection. Urine tests show that most patients experiencing delirium have bacteria in their urine, however, bacteria in the urine is common among older adults, and does not automatically indicate an infection is present. As a result it is difficult to know whether a lower urinary tract infection is present as individuals with delirium are frequently unable to report clinical signs of infection - symptoms of pain or discomfort with urination, having to urinate more frequently or pelvic discomfort. Very often, individuals with delirium are treated with antibiotics despite the fact that it is unknown whether antibiotics help to improve delirium in cases where bacteria in the urine is present. This proposed study is a randomized controlled trial that will examine if adults (age 60 or older) with delirium and suspected infection benefit from taking antibiotics.",[23],[403,404,405,406],"Delirium","Antibiotics","Older adults","Urinary Tract Infection","2024-09-09",{"date":409,"type":28},"2024-09-19",{"date":411,"type":28},"2024-05-18",{"date":413,"type":19},"2027-09",{"name":415,"class":35},"Mount Sinai Hospital, Canada",{"id":417,"slug":418,"hasResults":11,"nctId":419,"briefTitle":420,"officialTitle":421,"acronym":4,"eligibilityCriteria":422,"healthyVolunteers":45,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":423,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":425,"conditions":426,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":429,"lastUpdatePostDateStruct":430,"startDateStruct":432,"completionDateStruct":434,"leadSponsor":436,"locationsCount":159},"100553907","triage-survey-for-infectious-disease-eligibility-100553907","NCT06492187","Triage Survey for Infectious Disease Eligibility","Triage Survey for Infectious Disease Eligibility (SWIFT-ID-101)","Inclusion Criteria:\n\n\\- 1. Participant or Legally Authorized Representative has signed an ICF prior to study-specific procedures being performed.\n\n2\\. Participant is at least 18 years old.\n\nExclusion Criteria:\n\n1. Participants are pregnant, breast-feeding, or planning to become pregnant.\n2. History of a clinically significant illness which in the investigator's opinion may impact participant safety or the ability to analyze study results or makes them unsuitable for the study for another reason.\n3. Current or recent moderate or severe substance use disorder impacting their ability to follow study related procedures.\n4. Reported history of coagulopathy or bleeding disorder considered a contraindication to phlebotomy.\n5. Any condition that in the investigator's opinion makes a participant unsuitable for the clinical trial study.\n6. Currently employed by Swift Clinical Research Group, Inc. or any of its subsidiaries, including Brooklyn Clinical Research, or a first-degree relative of an employee.",{"count":424,"type":19},10000,"SWIFT-ID-101 is a single site survey study designed to assess potential participants' eligibility to screen for industry-sponsored clinical trials for diagnosis, treatment, or prevention of infectious diseases such as in the areas of HIV, vaccines, and other infectious-diseases areas. A physician will oversee the informed consent process, after which participants will be surveyed on demographics, medical\u002Fsurgical history, physical examination, comorbidities, and any current symptoms. Informed consent will be done electronically (preferable) or on paper. Informed consent may be done in-person or remotely, depending on patient preference. Information related to HIV, hepatitis B and C, other infectious diseases, or substance use disorder will also be obtained if applicable. Site staff may collect vital signs, fingerpick testing, urine drug screens, blood draws, EKG, and pregnancy tests. Some testing may be recommended in a fasting condition. A doctor will review medical history and results of the above evaluations with the participant to determine study suitability via clinical interview. The doctor may reach out to the patient's current treating physicians, other providers, and pharmacies to determine eligibility for clinical trials. A follow-up phone call may be needed to discuss testing results and\u002For trial eligibility. If a participant is deemed eligible for future trials and if the participant remains interested, counseling on contraception requirements for trials will be discussed.",[427,428,23],"Vaccination; Infection","HIV-1-infection","2024-07-01",{"date":431,"type":28},"2024-07-09",{"date":433,"type":28},"2024-06-28",{"date":435,"type":19},"2029-01-28",{"name":437,"class":438},"Brooklyn Clinical Research","NETWORK",{"id":440,"slug":441,"hasResults":11,"nctId":442,"briefTitle":443,"officialTitle":443,"acronym":4,"eligibilityCriteria":444,"healthyVolunteers":45,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":445,"targetDuration":447,"studyType":20,"phases":4,"briefSummary":448,"conditions":449,"keywords":470,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":473,"startDateStruct":475,"completionDateStruct":477,"leadSponsor":478,"locationsCount":159},"100440334","anovaos-network-powered-patient-registry-100440334","NCT05013944","AnovaOS Network Powered Patient Registry","Inclusion Criteria:\n\n* 18 years old or older;\n* Confirmed positive diagnosis of disease, condition or disorder. This will be self-reported or reported by the patient's provider, advocacy group or other patient representative;\n* Laboratory or other independent means of confirmation is not required but may be confirmed in clinical trials;\n* Able to understand and willing to sign the informed consent document; or whose legal representative has given consent to participate in the research per state and Federal requirements;\n* Willing and able to complete the registry questions or have the instrument(s) completed by an informed proxy;\n* Anticipated additional follow up with the registry once per year.\n\nExclusion Criteria:\n\n* Subjects who do not meet the inclusion criteria for the study;\n* Subjects who are unable to understand the protocol or unable to provide legally effective informed consent",{"count":446,"type":19},100000,"5 Years","The objective of this study is the development, implementation and management of a registry of patient data that captures clinically meaningful, real-world, data on the diagnosis, nature, course of infection, treatment(s) and outcomes in patients with complex disease globally.",[23,450,451,452,453,454,455,456,457,458,459,460,461,462,463,464,465,466,467,468,469],"Neoplasms","Diseases of the Blood and Blood-Forming Organs and Certain Disorders Involving the Immune Mechanism (D50-D89)","Endocrine, Nutritional and Metabolic Diseases (E00-E89)","Mental and Behavioural Disorders","Diseases of the Nervous System","Diseases of the Eye and Adnexa","Diseases of the Ear and Mastoid Process","Diseases of the Circulatory System","Diseases of the Respiratory System","Diseases of the Digestive System","Diseases of the Skin and Subcutaneous Tissue","Diseases of the Musculoskeletal System and Connective Tissue","Diseases of the Genitourinary System","Pregnancy, Childbirth and the Puerperium","Certain Conditions Originating in the Perinatal Period","Congenital Malformations, Deformations and Chromosomal Abnormalities (Q00-Q99)","Symptoms, Signs and Abnormal Clinical and Laboratory Findings, Not Elsewhere Classified","Injury, Poisoning and Certain Other Consequences of External Causes","External Causes of Morbidity and Mortality","Factors Influencing Health Status and Contact With Health Services",[471],"infectious disease, cancer\u002Foncology, neurology, immunology, cardiology","2024-01-29",{"date":474,"type":28},"2024-01-30",{"date":476,"type":28},"2021-09-01",{"date":365,"type":19},{"name":479,"class":199},"Anova Enterprises, Inc",{"id":481,"slug":482,"hasResults":11,"nctId":483,"briefTitle":484,"officialTitle":485,"acronym":4,"eligibilityCriteria":486,"healthyVolunteers":45,"sex":15,"minAge":487,"maxAge":488,"enrollmentInfo":489,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":490,"conditions":491,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":498,"lastUpdatePostDateStruct":499,"startDateStruct":501,"completionDateStruct":503,"leadSponsor":505,"locationsCount":99},"100350911","collection-and-distribution-of-biospecimens-for-novel-research-uses-100350911","NCT03848962","Collection and Distribution of Biospecimens for Novel Research Uses","iSpecimen Network Protocol: Collection and Distribution of Remnant and Research Use Only Biospecimens for Novel Research Uses","Inclusion Criteria:\n\n* Individual is developmentally aged 7 years old and above for RUO collections (only)\n* Individual meets requirements of a current request for research materials from iSpecimen\n* If a blood collection will be performed as part of the screening process or RUO collection, the individual's health will be assessed by medical staff through medical record review, clinical exam, and\u002For the review of an updated medical history as provided by the participant\n* Individual has reviewed and signed a consent form for an RUO specimen collection if required as part of the research or if a minor or a person with diminished decision-making capacity, their parent\u002Fguardian or Legally Authorized Representative has reviewed and signed the consent form on their behalf.\n* Individual has reviewed and signed a consent form for remnant specimen usage in research if required as part of the research or if a minor or a person with diminished decision-making capacity, their parent\u002Fguardian or Legally Authorized Representative has reviewed and signed the consent form on their behalf\n\nExclusion Criteria:\n\n* Subjects that do not meet the inclusion criteria outlined above.","1 Month","89 Years",{"count":424,"type":19},"iSpecimen aims to create a clinical partner network of hospitals, laboratories, academic institutions, and other healthcare organizations (\"institutions\") capable of providing researchers and educators (\"researchers\") with annotated biospecimens for use in biomarker discovery and validation; diagnostic test and instrumentation development and validation; therapeutics development; other medical research including the impact that various specimen collection and handling methods and conditions have on research results; and in education such as researcher or physician training (collectively \"research\").",[379,492,493,494,23,495,496,497],"Healthy","Gastrointestinal Complication","Autoimmune Diseases","Women's Health: High-Risk Pregnancy","Dermatologic Disease","Blood Disease","2022-11-08",{"date":500,"type":28},"2022-11-09",{"date":502,"type":28},"2016-06-30",{"date":504,"type":19},"2026-12-31",{"name":506,"class":199},"iSpecimen Inc"]